Recombinant Human IL-29/IFN-lambda 1 Protein, CF

Catalog #: 11240-IL Datasheet / COA / SDS

E. coli-expressed

Catalog #	Availability	Size / Price	Qty
11240-IL-050

Recombinant Human IL-29/IFN-lambda 1 Protein Bioactivity.

1 Image

All IL-29/IFN-lambda 1 Proteins and Enzymes

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human IL-29/IFN-lambda 1 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED₅₀ for this effect is 0.500-6.00 ng/mL.

Source

E. coli-derived human IL-29/IFN-lambda 1 protein
Pro23-Thr200

Accession #

Q8IU54.1

N-terminal Sequence
Analysis

Pro23

Predicted Molecular Mass

20 kDa

SDS-PAGE

18-22 kDa, under reducing conditions.

Product Datasheets

11240-IL

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11240-IL

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human IL‑29/IFN‑lambda 1 Protein (Catalog # 11240-IL) demonstrates anti-viral activity in HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED₅₀ for this effect is 0.500-6.00 ng/mL.

Reconstitution Calculator

Background: IL-29/IFN-lambda 1

IL-29, also known interferon-lambda 1 (IFN lambda 1), along with IL-28A (IFN lambda 2), IL-28B (IFN lambda 3) and IFN lambda 4, collectively comprise the type III subset of IFNs. IFN lambda s are class II cytokine receptor ligands distantly related to both members of the IL-10 family and to the type I IFN family (11-19% amino acid (aa) sequence identity). IL-29 is expressed only in humans and shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively. IFN lambda signaling was initially thought to be restricted to epithelial cells, but, recently, additional cell types have been shown to also respond. IFN lambda s have been shown to be induced by a variety of stimuli from influenza A and herpes viruses to lipopolysaccharides and double-stranded RNA. IL-29 signals through a unique receptor complex composed of IFN lambda R1 (IL-28RA) and the shared IL-10R2 chain, which is also a part of the receptor complexes for IL-10, IL-22, and IL-26. In humans, IL-29 is the most potent IFN lambda molecule, the most abundant IFN lambda molecule in serum, and the only IFN lambda molecule to display N-linked glycosylation. IL-29 is being investigated for its role in immunity, both innate and adaptive, as well as in autoimmune disorders. Additionally, the therapeutic potential of IL-29 in inflammatory diseases and its cancer fighting properties are being actively studied.

References

Vilcek, J. (2003) Nature Immunol. 4:8.
Sheppard, P. et al. (2003) Nature Immunol. 4:63.
Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
Gad, H.H. et al. (2009) J. Biol. Chem. (2009) 284:20869.
Miknis, Z.J. et al. (2010) J. Mol. Biol. 404:650.
Donnelly, R.P. et al. (2010) J. Interferon. Cytokine Res. 30:555.
Lazear, H.M. et al. (2015) Immunity. 43:15.
Ye, L. et al. (2019) Nat. Rev. Immunol. 19:614.
Goel, R.R. et al. (2021) Nat. Rev. Rheumatol. 17:349.
Kelm, N.E. et al. (2016) Crit. Rev. Oncol. Hematol. 106:91.
Wang, J.M. et al. (2019) J. Cell Mol. Med. 23:7926.

Long Name

Interleukin 29

Entrez Gene IDs

282618 (Human)

Alternate Names

cytokine Zcyto21; IFNL1; IFN-lambda 1; IFN-lambda-1; IL29; IL-29; interferon lambda-1; interferon, lambda 1; interleukin 29 (interferon, lambda 1); interleukin-29; ZCYTO21